Japan Cell and Gene Therapy Market Outlook: Advanced Biotech Innovation, Personalized Medicine & Growth Opportunities

According to IMARC Group's latest research publication, the Japan cell and gene therapy market size was valued at USD 814.2 Million in 2025. Looking forward, IMARC Group estimates the market to reach USD 2,151.4 Million by 2034, exhibiting a CAGR of 11.40% from 2026-2034.

How AI is Reshaping the Future of Japan Cell and Gene Therapy Market

• AI-Driven Target Discovery: Machine learning models scan genomic and proteomic datasets to identify viable gene therapy targets faster than traditional lab methods, compressing early-stage R&D timelines and helping Japanese biotech firms prioritize the most promising candidates.
• Predictive Patient Matching: AI algorithms analyze patient genetic profiles and disease histories to match individuals with the most suitable cell or gene therapy, improving trial enrollment efficiency and boosting the precision of treatment outcomes across oncology and rare disease programs.
• Automated Cell Manufacturing: AI-powered bioprocessing systems monitor and adjust cell culture conditions in real time, improving batch consistency and yield for CAR-T and stem cell therapies, directly addressing one of the biggest scalability challenges in Japan's production pipeline.
• Real-Time Safety Monitoring: AI tools continuously analyze post-treatment patient data to detect early adverse signals, giving clinicians faster visibility into therapy safety and enabling quicker regulatory responses under Japan's Act on the Safety of Regenerative Medicine.
• Gene Editing Optimization: AI models simulate CRISPR editing outcomes across thousands of genomic sequences, helping researchers in Japan identify off-target risks before clinical application and improving the precision and safety profile of next-generation gene therapies.

How Japan's Government Initiatives are Revolutionizing the Cell and Gene Therapy Industry

Japan has built one of the most forward-thinking regulatory environments for regenerative medicine anywhere in the world. The Act on the Safety of Regenerative Medicine introduced an accelerated approval pathway that lets promising cell and gene therapies reach patients earlier, while conditional approvals allow products to be commercialized based on interim efficacy data as long as post-market surveillance continues. The government backs this framework with direct funding through agencies like the Japan Agency for Medical Research and Development (AMED), which channels grants into academia-industry collaborations and clinical trial programs. The Development Bank of Japan reinforced this commitment through its investment in 4BIO Ventures III LP, a biotech fund focused on early-stage cell and gene therapy ventures with a presence across Japan, Europe, and North America. Together, these policy and financial levers have turned Japan into a genuinely competitive destination for global regenerative medicine investment, with Tokyo's Kanto region and Osaka's Kansai cluster attracting the bulk of R&D activity.

Request a Sample Report with the Latest Data & Forecasts

Japan Cell and Gene Therapy Market Trends & Drivers

Japan's aging population is one of the clearest structural drivers behind this market's growth. With roughly 30% of the population aged 65 or older, the country carries one of the heaviest chronic disease burdens among developed nations, with high rates of cardiovascular conditions, cancer, and rare genetic disorders. These are precisely the conditions where cell and gene therapies are showing the most clinical promise. CAR-T therapies for relapsed blood cancers and stem cell treatments for heart tissue repair are both advancing through Japan's clinical pipeline, supported by a regulatory system designed to move innovative treatments faster than most global counterparts. Bristol-Myers Squibb received manufacturing and marketing approval for Abecma, a BCMA-directed CAR-T immunotherapy, specifically targeting Japanese patients with relapsed or refractory multiple myeloma who have exhausted prior treatment lines.

Academia and industry working closely together is not a nice-to-have in Japan's cell and gene therapy market; it is a structural feature. The CiRA Foundation, Japan's leading iPS cell research group, partnered with Terumo BCT to build an automated, clinically scalable workflow for iPS cell-derived therapies, combining CiRA's cell biology expertise with Terumo's manufacturing and bioprocessing technology. Synplogen, a Kobe University spinout, signed an MOU with Ginkgo Bioworks to accelerate global gene therapy platform services and DNA production from Japan. These collaborations are not just symbolic; they are closing the gap between laboratory discovery and commercial-scale production, which remains the most critical bottleneck in the broader cell and gene therapy field globally.

Manufacturing capacity is the next frontier, and Japan is investing in it deliberately. AGC Biologics is preparing its Yokohama site to launch cell therapy CDMO services, with partial operations beginning ahead of the full launch, following a partnership agreement with MEDINET that embeds personnel and knowledge transfer directly into the process. Teijin Limited signed an MOU with Singapore-based Hilleman Laboratories to build out international CDMO capabilities in the cell and gene therapy space. PHC Corporation commercially launched LiCellMo, a live cell metabolic analyzer that enables real-time monitoring of cellular metabolites in culture without interrupting the experiment, giving researchers sharper visibility into cell behavior during manufacturing. These moves collectively signal that Japan is not just developing therapies; it is building the industrial backbone needed to produce them at scale.

Japan Cell and Gene Therapy Market Industry Segmentation

The report has segmented the market into the following categories:

Therapy Type Insights:

• Cell Therapy
• Stem Cell
• Non-Stem Cell
• Gene Therapy

Indication Insights:

• Cardiovascular Disease
• Oncology Disorder
• Genetic Disorder
• Infectious Disease
• Neurological Disorder
• Others

Delivery Mode Insights:

• In-Vivo
• Ex-Vivo

End User Insights:

• Hospitals
• Cancer Care Centers
• Pharmaceutical and Biotechnology Companies
• Others

Regional Insights:

• Kanto Region
• Kansai/Kinki Region
• Central/Chubu Region
• Kyushu-Okinawa Region
• Tohoku Region
• Chugoku Region
• Hokkaido Region
• Shikoku Region
• Competitive Landscape

The competitive landscape of the industry has also been examined along with the profiles of the key players.

Recent News and Developments in Japan Cell and Gene Therapy Market

• December 2023: Bristol-Myers Squibb K.K. received manufacturing and marketing approval for a supplemental New Drug Application for Abecma (idecabtagene vicleucel), a BCMA-directed CAR-T immunotherapy, covering patients with relapsed or refractory multiple myeloma who have received at least two prior therapies including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody.
• March 2024: The CiRA Foundation and Terumo BCT announced a collaboration to develop an automated, clinically relevant manufacturing workflow for iPS cell-derived therapies, combining CiRA's leading iPS cell science with Terumo BCT's bioprocessing expertise to accelerate the path from research to scalable treatment delivery.
• July 2024: The National Cancer Center Japan and the University of Pennsylvania licensed CCR4 CAR-T cell therapy patent rights to ARC Therapies Inc., a National Cancer Center spinout, initiating R&D targeting adult T-cell leukemia/lymphoma and exploring potential applications in solid cancers prevalent in Japan.
• September 2024: AGC and MEDINET finalized a partnership agreement for the cell therapy CDMO business, with AGC embedding staff at MEDINET to build Japan-specific expertise and preparing its Yokohama site for cell therapy CDMO services, with partial operations beginning ahead of the full scheduled launch.
• October 2024: Teijin Limited signed a Memorandum of Understanding with Singapore-based Hilleman Laboratories to develop a strategic international commercial cooperation in the cell and gene therapy CDMO sector, expanding Teijin's footprint in contract development and manufacturing for advanced therapies.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.